IMS 2186 is an anti-choroidal neovascularization agent. It inhibits proliferation of NIH3T3 mouse and IMR-90 human fibroblasts (ICs = 0.5-3 µM), as well as in a panel of eight human cancer cell lines, including ovarian, lung, colon, and pancreatic cancer cells (ICs = 0.3-3 µM). IMS 2186 (10 µM) decreases migration of THP-1 macrophages in wound healing and chamber assays. Subcutaneous administration of IMS 2186 (20 µg/animal) inhibits VEGF-induced blood vessel formation in a Matrigel plug assay in mice. It reduces ocular leakage, as well as cellular proliferation and infiltration in a rat model of laser-induced choroidal neovascularization when administered intravitreally at a dose of 100 µg/eye.